ma.ilunga
Submits third-party assay reports on material purchased directly. Based in Tours.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
6
n=6
Annotations
0
n=0
Median purity submitted
98.79%
n=6
Suppliers covered
6
n=6
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041789 | Retatrutide | ASY | ASY-{CAT}-2288 | Janoshik | 2026-Q3 | 98.37 | 6.19 | 99.4 | Buyer-sourced | 0 | PASS |
| AX-2026-041704 | BPC-157 | TFS | TFS-{CAT}-9814 | Janoshik | 2026-Q2 | 99.24 | 3.91 | 96.3 | Buyer-sourced | 0 | PASS |
| AX-2025-019287 | CJC-1295 (no DAC) | AMB | AMB-2508-F5378 | PeptideMeter | 2025-Q3 | 99.21 | 2.97 | — | Buyer-sourced | 0 | PASS |
| AX-2025-019662 | Afamelanotide | TFC | TFC-2502-Y2346 | VendorInvestigate | 2025-Q1 | 99.32 | 4.74 | 106.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2024-005300 | Tirzepatide | BCH | BCH-2404-N5218 | Janoshik | 2024-Q3 | 97.73 | 3.35 | 102.9 | Buyer-sourced | 0 | PASS |
| AX-2024-005206 | Semaglutide | CPC | CPC-2309-A1413 | Janoshik | 2024-Q1 | 97.90 | 5.61 | — | Buyer-sourced | 0 | PASS |